Abstract
Objective
The aim of the present study was to consider the safety and efficacy of concurrent use of strontium-89 (Sr-89) with external beam radiotherapy (EBRT) for multiple bone metastases, including lesions that require urgent therapy.
Methods
A retrospective review was performed of a consecutive series of patients who received Sr-89 for multiple bone metastases. Forty-five patients with multiple bone metastases received Sr-89 injection. Since 17 of the 45 patients had osteolytic bone lesions requiring emergent EBRT, they underwent concurrent use of Sr-89 with EBRT (concurrent group). The remaining 28 patients, none of whom had osteolytic lesions requiring urgent EBRT, were given Sr-89 injection only (singularity group). The injection of Sr-89 was to be given during EBRT, or on the day before the first day of EBRT. The dose of EBRT was 30 Gy in 10 fractions or 40 Gy in 20 fractions. Adverse events were evaluated according to hematological toxicity as measured by the Common Terminology Criteria for Adverse Events (V4.0). To assess efficacy, we checked changes in the pain scale and analgesic drug dosages, and the presence or absence of serious complications from bone metastases.
Results
Fifteen of 17 patients (88.2 %) in the concurrent group and 17 of 28 patients (60.7 %) in the singularity group reported bone pain relief. A statistically significant difference was found between the two groups, and severe complications (spinal cord compression and pathological fracture) from bone metastases could be prevented in all patients in the concurrent group. Severe hematological toxicity (grade 3 or higher) was not observed in the two groups. There was no statistical difference between the two groups. No one required additional intervention. The adverse events were tolerable.
Conclusions
The results of our study suggest that concurrent use of Sr-89 with EBRT for multiple bone metastases can be performed safely if it is carried out with care, and that it may be an effective therapy in cases requiring emergency treatment.
Similar content being viewed by others
References
Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392–400.
Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893–9.
Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–6.
Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment-current and future. Int J Clin Oncol. 2008;13:18–23.
Bruckman JE, Bloomer WD. Management of spinal cord compression. Semin Oncol. 1978;5:134–40.
Gilbert RW, Kim JH. Posner. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3:40–51.
Ruff RL, Lanska DJ. Epidural metastases in prospectively evaluated veterans with cancer and back pain. Cancer. 1989;63:2234–41.
McEwan AJ. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med. 1997;27:165–82.
Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007;28:245–50.
Lipton A, Costa L, Ali SM, Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev. 2001;27:181–5.
Serafini AN. Current status of bone pain palliation with systemic radioisotopes. Nucl Med Ann. 2002;1:253–74.
Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, Arndt JW, Zwinderman AH, Papapoulos SE, et al. Strontium-89(Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging. 2002;29:494–8.
Yamada K, Yoshimura M, Kaise H, Ogata A, Ueda N, Tokuuye K, et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med. 2012;3:226–30.
Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.
McEwan AJ, Porter AT, Venner P, Amyotte G. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunoconjugates Radiopharmaceuticals. 1990;3:91–7.
Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases ver.3.0 (http://interactive.snm.org/docs/pg_ch25_0403.pdf). Accessed 5 Aug 2015.
Silberstein EB, Taylor AT Jr, EANM. EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2003;30:BP7–11.
Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Logothetis CJ, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23:7904–10.
Acknowledgments
We are grateful to Keiichiro Yamaguchi, Vice president of Sendai Kousei Hospital, for his guidance on the proper use of Sr-89.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Heianna, J., Toita, T., Endo, W. et al. Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience. Ann Nucl Med 29, 848–853 (2015). https://doi.org/10.1007/s12149-015-1010-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-015-1010-6